October 13, 2014 | The Israeli pharmaceutical technology company Therapix Biosciences registered with the American Depository Receipts to begin trading on Wall Street’s OTCQB exchange. Therapix currently has a NIS 9.3 million market cap on the Tel Aviv Stock Exchange, and following the announcement, the company’s share price rose 10 percent only to drop by 11 percent in the subsequent days. Therapix now hopes that trading on Wall Street will improve its situation, as medical marijuana research companies have seen a downturn since the beginning of 2014. Therapix focuses on the advancement of specialty biopharmaceuticals, recently investing in medical marijuana company Lara Pharma.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments